FDA

Human liver
#FDA #Fibrosis #GLP-1 #Liver disease #Novo Nordisk

Wegovy granted accelerated approval in the US for liver disease

The US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4mg) as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).  The approval is in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet… Read More

#News #Regulatory #Trending News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to… Read More

#News #Regulatory

Drug manufacturing
#FDA #Manufacturing #United States

US initiative to reduce reliance on foreign drug manufacturing

The US Food and Drug Administration (FDA) has introduced FDA PreCheck, a new programme to facilitate the construction of manufacturing sites.  More than half of pharmaceuticals distributed in the US are manufactured overseas and the US is reliant on overseas sources for active pharmaceutical ingredients (APIs).  “Our gradual overreliance on… Read More

#Business & Investment #News #Regulatory

Human brain
#Brain cancer #FDA #Jazz Pharmaceuticals #Oncology

FDA approves first treatment for rare type of glioma

The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy.  The FDA has stated that continued approval for this indication… Read More

#News #Regulatory

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).  … Read More

#Cancer Research #News #Regulatory

Multiple myeloma
#FDA #GSK #Monoclonal antibodies #Myeloma #Oncology

FDA committee votes against Blenrep combinations for myeloma

The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile at GSK’s proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.   The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line… Read More

#News #Regulatory

FDA
#AAV #FDA #Gene therapy #Manufacturing #Rare disease #Ultragenyx

FDA raises manufacturing concerns for Ultragenyx gene therapy

The US Food and Drug Administration (FDA) has decided not to recommend Ultragenyx Pharmaceutical’s UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).   In its complete response letter (CRL), the FDA requested that the company provide additional information and improvements related to… Read More

#News #Regulatory #Trending News

FDA headquarters
#Cancer research #Drug discovery #FDA #Fujifilm #Regulatory

FUJIFILM’s biliary tract cancer drug granted FDA orphan status

FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More

#Cancer Research #News

#Atsena Therapeutics #Clinical trial #FDA #Gene therapy #Ophthalmology

Atsena expedites gene therapy for X-linked retinoschisis

The US Food and Drug Administration (FDA) has agreed to the expansion of Atsena Therapeutics’ ongoing Phase I/II LIGHTHOUSE study of ATSN-201 into a continuous Phase I/II/III trial in the treatment of X-linked retinoschisis (XLRS).   “This regulatory milestone marks another significant step toward delivering a potentially first- and best-in-class gene… Read More

#News #Regulatory

Prostate cancer cells
#Archeus Technologies #FDA #Oncology #Phase I trial #Prostate cancer #Radiopharmaceuticals

FDA clears radiopharmaceutical for prostate cancer

The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More

#Cancer Research #News #Regulatory

FDA headquarters
#CAR-T #Cell therapy #FDA #Immunotherapy #Regulatory

FDA removes barriers to CAR-T access in the US

The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been removed.  The Food and Drug Administration (FDA) has determined that a REMS is no longer necessary to ensure that the benefits of these CAR T cell immunotherapies… Read More

#News #Regulatory

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was approved under accelerated approval based… Read More

#News #Regulatory #Trending News

FDA headquarters
#Fast Track designation #FDA #Regulatory #United States

FDA priority programme reduces drug reviews to two months

The US Food and Drug Administration (FDA) has revealed plans to issue new Commissioner’s National Priority Vouchers (CNPVs) to companies “supporting US national interests”.  The new voucher may be redeemed by drug developers to participate in a novel priority programme that shortens drug review time from approximately 10-12 months to… Read More

#News #Regulatory #Trending News

Baby on a respirator - RSV
#FDA #Merck #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

FDA approves Merck’s Enflonsia for RSV prevention

The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season.   Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct,… Read More

#News #Regulatory

Synsapses
#Amyotrophic lateral sclerosis (ALS) #FDA #Neuroscience #Orphan drugs #Spinogenix

First synaptic regenerative therapy for ALS gets orphan status

The European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Spinogenix’s SPG302 for the treatment of people living with amyotrophic lateral sclerosis (ALS).   SPG302 is being developed as the first synaptic regenerative approach for the treatment of ALS, with the potential to restore function in cognition, movement, and… Read More

#Editor's Choice #News #Regulatory

Sickle cells
#FDA #Orphan drugs #Rare disease #Sanofi #Sickle cell disorder (SCD)

Sanofi gets fourth orphan drug designation for rilzabrutinib

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib for sickle cell disease (SCD).  Rilzabrutinib is an oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation.  BTK, expressed in B… Read More

#News #Regulatory